Psilocybin - Mydecine Innovations Group
Alternative Names: MYCO 001; MYCO 003Latest Information Update: 01 Jul 2022
At a glance
- Originator Mydecine Innovations Group
- Developer Applied Pharmaceutical Innovation; Mydecine Innovations Group; University of Maryland, Baltimore
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Post-traumatic stress disorders
- Research Anxiety disorders; Depressive disorders; Headache; Substance-related disorders
Most Recent Events
- 17 Jun 2022 US FDA approves IND application for Psilocybin for Smoking Withdrawal
- 09 Jun 2022 Mydecine Innovations Group plans a phase III trial for Smoking withdrawal
- 31 Mar 2022 Mydecine Innovations Group announces intention to submit an IND application to the US FDA for Smoking withdrawal in early Q4 2022